HCAR-4

N/A

Report date: 2024/03/29 15:31:43

Base Information

Drug NameHCAR-4

Drug Alias NameHCAR-4HCAR4

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionClaudin 18 protein modulators

TargetsClaudin-18 splice variant 2

Therapy Area/IndicationsStomach NeoplasmsEsophageal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIndia

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesImmunoACT Ltd

China Registration ClassN/A

Develop Information

Active CompaniesImmunoACT Ltd

Inactive CompaniesN/A

Active IndicationsStomach NeoplasmsEsophageal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A